Cytosorbents Corp (NASDAQ:CTSO) 2018 Q1 Sentiment Change, Now at 2.36

June 26, 2018 - By Alex Paulin

Cytosorbents Corporation (NASDAQ:CTSO) Corporate Logo

Cytosorbents Corp’s Sentiment

“Big money sentiment for Cytosorbents Corp (NASDAQ:CTSO) in Q1 2018 decreased to 2.36, according to Securities and Exchange Commission filings. That’s down -0.53, from 2017Q4’s 2.89. 26 active investment managers started new and increased positions, while 11 sold and trimmed holdings in Cytosorbents Corp so the sentiment dropped. Funds own 3.72 million shares, up from 2.91 million shares in 2017Q4. Funds holding Cytosorbents Corp in top 10 changed to 1 from 0 for an increase of 1. In total 4 funds closed positions, 7 reduced and 16 increased. Also 10 funds bought new Cytosorbents Corp stakes.

Significant Cytosorbents Corp Investors

As of Q1 2018 Fortaleza Asset Management Inc has 1.61% invested in Cytosorbents Corp. As of Q1 2018, 246,200 shares of Cytosorbents Corp are owned by Manatuck Hill Partners Llc. In addition, Skylands Capital Llc reported 686,950 shares in Cytosorbents Corp equivalent to 0.64% of its equity exposure. Eam Investors Llc revealed 85,967 shares position in Cytosorbents Corp. The California-based fund Granite Investment Partners Llc holds 58,851 shares or 0.03% of their equity exposure.

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology.The firm is valued at $322.21 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.Currently it has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

CTSO reached $10.73 during the last trading session after $0.08 change.Cytosorbents Corporation has volume of 35,934 shares. Since June 26, 2017 CTSO has risen 156.32% and is uptrending. CTSO outperformed the S&P500 by 143.75%.

On August, 6. Investors wait Cytosorbents Corporation (NASDAQ:CTSO) to publish its quarterly earnings, as reported by Faxor. Last year’s earnings per share was $-0.04, while now analysts expect change of 225.00 % down from current $-0.13 earnings per share. Last quarter $-0.10 earnings per share was reported. Analysts predicts 30.00 % negative EPS growth this quarter.

Barclays Public Ltd Co invested 0% of its capital in Cytosorbents Corporation (NASDAQ:CTSO). California Pub Employees Retirement owns 46,100 shs for 0% of their capital. Manatuck Hill Ptnrs Ltd Liability holds 0.92% in Cytosorbents Corporation (NASDAQ:CTSO) or 246,200 shs. Morgan Stanley accumulated 0% or 23,193 shs. Tower Cap Limited Liability Company (Trc) stated it has 1,072 shs or 0% of all its holdings. Citadel Advisors Lc owns 11,291 shs or 0% of their US capital. 42,013 were accumulated by Goldman Sachs Grp. Northern holds 48,114 shs. Fortaleza Asset Mgmt holds 1.61% or 37,615 shs in its capital. Credit Suisse Ag reported 0% in Cytosorbents Corporation (NASDAQ:CTSO). Vanguard Group holds 0% or 998,726 shs. Crow Point Ptnrs Llc has 0.01% invested in Cytosorbents Corporation (NASDAQ:CTSO) for 10,656 shs. Bluecrest Cap Management owns 73,907 shs. Granite Partners Limited Liability accumulated 58,851 shs or 0.03% of the stock. Thompson Davis & has 1,250 shs.

Cytosorbents Corporation registered $1.06 million net activity with 0 insider purchases and 11 insider sales since January 8, 2018. 7,154 shs were sold by Capponi Vincent, worth $64,386.

Cytosorbents Corporation (NASDAQ:CTSO) Ratings Coverage

In total 2 analysts cover Cytosorbents Corp (NASDAQ:CTSO). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CTSO) has 100% bullish analysts. 4 are the (NASDAQ:CTSO)’s ratings reports on 26 Jun 2018 according to StockzIntelligence Inc. On Tuesday, January 9 the firm has “Buy” rating by H.C. Wainwright given. On Wednesday, May 9 the rating was maintained by H.C. Wainwright with “Buy”. The company rating was maintained by H.C. Wainwright on Friday, March 9. On Thursday, March 8 the rating was maintained by Cowen & Co with “Buy”.

More recent Cytosorbents Corporation (NASDAQ:CTSO) news were brought out by Benzinga.com, Prnewswire.com and Prnewswire.com. The first one has “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” as a title and was brought out on June 15, 2018. The next is “CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference” on June 04, 2018. And last was brought out on June 26, 2018, called “CytoSorbents Added to the Russell 2000 and Russell 3000 Indexes”.

Cytosorbents Corporation (NASDAQ:CTSO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.